Drug-induced atrial fibrillation

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a prevalent cardiac arrhythmia with serious health implications.
• Drug-induced arrhythmias are well-recognized, but attributing AF to specific medications is challenging.
• Risk factors like age, hypertension, and heart disease increase susceptibility to drug-associated AF.

Purpose of the Study:

• To review the association between drug therapy and new-onset atrial fibrillation.
• To identify specific drug classes implicated in precipitating AF.
• To emphasize the importance of considering drug-induced causes in AF diagnosis.

Main Methods:

• Literature review of studies reporting drug-associated atrial fibrillation.
• Analysis of case reports and clinical data linking medications to AF onset.
• Evaluation of risk factors and comorbidities in patients with drug-induced AF.

Main Results:

• Certain cardiovascular drugs (adenosine, dobutamine, milrinone) are linked to new-onset AF.
• Medications like corticosteroids, ondansetron, and antineoplastics (paclitaxel, mitoxantrone, doxorubicin) have also been reported to induce AF.
• The role of bisphosphonates in AF induction remains under investigation.

Conclusions:

• Drug-induced AF is a potential, though often difficult to confirm, complication.
• Healthcare providers should consider medication history in patients presenting with new-onset AF.
• Further research is needed to clarify the association between certain drugs, like bisphosphonates, and AF.